Form 8-K - Current report:
SEC Accession No. 0001193125-25-073937
Filing Date
2025-04-07
Accepted
2025-04-07 07:12:51
Documents
16
Period of Report
2025-04-02
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d875125d8k.htm   iXBRL 8-K 28292
2 EX-99.1 d875125dex991.htm EX-99.1 10914
6 GRAPHIC g875125g0404074824475.jpg GRAPHIC 2721
7 GRAPHIC g875125g0405012627956.jpg GRAPHIC 2384
  Complete submission text file 0001193125-25-073937.txt   178502

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20250402.xsd EX-101.SCH 2855
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20250402_lab.xml EX-101.LAB 17993
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20250402_pre.xml EX-101.PRE 11264
19 EXTRACTED XBRL INSTANCE DOCUMENT d875125d8k_htm.xml XML 3670
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 25816356
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)